Appraising iniparib, the PARP inhibitor that never was--what must we learn?

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Poly(ADP-ribose) polymerase (PARP) inhibitors show promise in treating cancers with BRCA1/BRCA2 mutations and sporadic ovarian cancer.
• Iniparib, a potential PARP inhibitor, demonstrated early success in triple-negative breast cancer (TNBC) but later failed in phase III trials.
• The failure of iniparib has raised questions about the efficacy of PARP inhibition as a therapeutic strategy.

Purpose of the Study:

• To scrutinize the development of iniparib from preclinical studies to registration trials.
• To identify and discuss pitfalls in anticancer drug development to prevent future late-stage trial failures.
• To clarify the role of PARP inhibition in cancer therapy.

Main Methods:

• Review of preclinical data and clinical trial results for iniparib.
• In vitro experiments to assess iniparib's inhibitory activity against PARP.
• Comparative analysis of iniparib's structure and function against other PARP inhibitors.

Main Results:

• Iniparib is structurally distinct from other PARP inhibitors and exhibits poor PARP inhibitory activity.
• Negative phase III trial results for iniparib may have inaccurately suggested that PARP inhibition is ineffective.
• The development pathway of iniparib highlights critical issues in anticancer drug evaluation.

Conclusions:

• Iniparib's failure should not be generalized to all PARP inhibitors.
• Understanding drug development pitfalls is crucial for advancing cancer therapeutics.
• Further research is needed to identify reliable biomarkers and optimize PARP inhibitor strategies.